Global Anti-Hypertensive Drugs Market

The drugs for hormonal replacement therapy are used to treat patients with growth hormone deficiency caused due to conditions such as dwarfism or menopause (a condition that describes changes a woman goes through when her menstruating cycle stops). The drugs for hormonal replacement therapy help to replace low-level hormones from the body, maintain growth hormone deficiency and prevent women from vaginal dryness, mood swings, weakening of bones, and others. The main types of drugs for hormonal replacement therapy are estrogen replacement therapy, human growth hormone (HGH) replacement therapy, thyroid replacement therapy, and testosterone replacement therapy. The various routes of administration are oral, parental, and others which are distributed in hospital pharmacies, retail pharmacies, and online pharmacies. The therapies are applied for hypothyroidism, male hypogonadism, growth hormone deficiency, menopause, and others. The drugs for hormonal replacement therapy market research report is one of a series of new reports from The Business Research Company that provides drugs for hormonal replacement therapy market statistics, including drugs for hormonal replacement therapy industry global market size, regional shares, competitors with drugs for hormonal replacement therapy market share, detailed drugs for hormonal replacement therapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for hormonal replacement therapy industry. This drug for hormonal replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drugs for hormonal replacement therapy market size will grow from $12.01 billion in 2022 to $12.66 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for hormonal replacement therapy market size is expected to grow to $14.63 billion in 2027 at a CAGR of 3.7%. The increasing population of aging and postmenopausal women is driving the drug market for hormonal replacement therapy. Hormonal replacement therapy drugs such as estrogen, progesterone, and others are used to treat medical conditions caused by menopausal conditions. For instance, in February 2021, according to the United Nations Economic and Social Commission for Asia and the Pacific, a Thailand-based regional commission, over half of the people who are over 65 are women, making up over 9% of the total population. By 2050, this percentage is projected to nearly double to more than 18%. From 1.7% to 4.9% of the population, the proportion of people over 80 will almost treble, with women making up over 60% of this group. There are a number of factors that could make older women more vulnerable than older men, including: According to the European Menopause and Andropause Society (EMAS) report, women aged over 60 are expected to reach over 1 billion by 2050. In South Korea, the female population is expected to exceed the male population by 2060, out of which 59.6% of the female population is expected to suffer from postmenopausal symptoms. Thus, the growing female population suffering from menopausal symptoms and the aging population drive the market for hormonal replacement therapy drugs. Increasing the occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder the growth of drugs for the hormonal replacement therapy market. The side effects include vagina dryness, irregular heartbeat, breast swelling, osteoporosis (weakening of bones), and other effects when women undergo hormone replacement therapy. A high dosage of drugs for hormonal replacement therapy may cause rapid heartbeat, bloating (a build-up of gas in the stomach and intestines), nausea, indigestion, vaginal bleeding, blood clots, heart attack, breast cancer, and others. According to an online study, a decrease in the intake of drugs for combined hormone therapy showed a decrease in breast cancer cases by 126,000 and cardiovascular disease cases by 76,000. Thus, the increasing side effects of drugs hinder the growth of drugs for hormonal replacement therapy. Companies in the industry are increasingly developing of drugs for hormonal replacement therapy with better safety profiles and novel drug delivery mechanisms. The drug delivery mechanisms include transdermal estrogen, virginal estrogen, and others. Transdermal estrogen drug delivery is in the form of estradiol transdermal gel, patch, and spray that are used to treat symptoms of menopause, vaginal dryness, itching, burning and others that occur due to low estrogen levels. Varginalestrogen in the form of cream, vaginal ring, and vaginal tablets is used to get the hormone estrogen into the system. For instance, Novo Nordisk, a multinational pharmaceutical company provides novel drug delivery mechanisms and low-dose drugs for hormonal replacement therapy (HRT) to cater to the rising demand of patient needs. Some of the brand’s offerings of novel drugs include Climara, Divigel, Elestrin, Esclim, Estraderm, Estrasorb, EstroGel, Evamist, Oesclim, Rhoxal-EstradiolDerm 50, Vivelle 100 Mcg, Estradot Transdermal Therapeutic System, and others. Department Of Health and Human Services of the Food and Drug Administration (FDA), a federal agency, is a regulatory body that monitors, controls, and regulates the drugs for the hormone replacement therapy market. For instance, the FDA's Department Of Health and Human Services has revised the requirements for specific hormone-containing drug products for human use. These hormones include estrogens, progestins, androgens, anabolic steroids, adrenal corticosteroids, and synthetic analogs. The purpose of the revisal of existing regulations by the FDA is to establish the effectiveness and ensure safety for any over-the-counter drug use of these ingredients. Major players in the drugs for hormonal replacement therapy market are Novartis AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Abbott, Mylan Laboratories, Merck & Co., Hisamitsu Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Noven Pharmaceuticals Inc., Orion Pharma AB, Allergan PLC., QuatRx Pharmaceuticals, Wyeth, Amgen Inc., Roche, Genentech, and TherapeuticsMD. North America was the largest region in the drugs for hormonal replacement therapy market in 2022. The Middle East is expected to be the fastest-growing region in the global drugs for hormonal replacement therapy market during the forecast period. The regions covered in the global drugs for hormonal replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for hormonal replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The drugs for hormonal replacement therapy market includes revenues earned by entities by treating common menopausal symptoms, including hot flashes and vaginal discomfort. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The global drugs for hormonal replacement therapy market is segmented - 1) By Therapy Type: Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, Other Applications 4) By Route of Administration: Oral, Parental, Other Route of Administration

Drugs for immunotherapy refer to a kind of medication that offers treatment to either stimulate or suppress the immune system in order to aid the body's protection against cancer, infection, and other disorders. Your immune system is assisted in fighting cancer via immunotherapy, a sort of cancer treatment. The body's immune system aids in the fight against infections and other disorders. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and they are used by various sectors such as hospitals and clinics, ambulatory surgical centres, and others. The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global drugs for immunotherapy market grew from $208.56 billion in 2022 to $231.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The drugs for immunotherapy market is expected to grow from $349.53 billion in 2027 at a CAGR of 10.9%. The immunotherapy drugs market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. For instance, in February 2022, according to a report shared by the WHO, a Switzerland-based specialised agency of the United Nations responsible for international public health, roughly 10 million deaths, or nearly one in six deaths, will be caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the market's growth. The high cost of immunotherapy drugs is acting as a restraint on the drugs for the immunotherapy market as a smaller number of patients can afford the treatment. Immunotherapy drugs are expensive as they are made specifically for each patient, and investment costs in the research and development are high. For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient, depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer, costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes them unaffordable, thereby affecting their market growth. Manufacturers of immunotherapy drugs are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilise Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy. Manufacturers of immunotherapy drugs are governed by various regulatory bodies, such as the Food and Drug Administration in the USA. The Food and Drug Administration (FDA) regulates drugs and biologics under the authority granted to it by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its amendments. Under this authority, FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics, depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins, and some nucleic acids. In August 2020, Bristol Myers Squibb, a US-based pharmaceutical company that manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders, acquired Dragonfly Therapeutics’ investigational immunotherapy program for $475 million. Through this acquisition, Bristol Myers Squibb will be granted Dragonfly’s extended half-life cytokine DF6002, a monovalent IL-12 immunoglobulin Fc. Dragonfly Therapeutics, Inc. is a US-based discovery-stage company developing drugs to stimulate immune responses against cancer. Major players in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen, Inc., AbbVie, Inc., and Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca PLC., Johnson & Johnson, and UbiVac. North America was the largest region in the immunotherapy market in 2022. The Middle East is expected to be the fastest growing region in the global drug for immunotherapy market during the forecast period. The regions covered in the global drugs for immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA. The drugs for immunotherapy market consists of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global drugs for immunotherapy market is segmented - 1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types 2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users

Immunosuppressant refers to a medication that prevents the immune system from attacking healthy cells and tissues. These medications are used to stop transplant rejection in recipients of stem cell and organ transplants. The medications also address the symptoms of autoimmune diseases. Immunosuppressants are potent medications that need to be carefully monitored to prevent side effects. The main classes of drugs in immunosuppressants are corticosteroids, monoclonal antibodies (MABs), calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different indications include organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The immunosuppressant market research report is one of a series of new reports from The Business Research Company that provides immunosuppressant market statistics, including the immunosuppressant industry's global market size, regional shares, competitors with an immunosuppressant market share, detailed immunosuppressant market segments, market trends and opportunities, and any further data you may need to thrive in the immunosuppressant industry. This immunosuppressant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global immunosuppressants market grew from $19.52 billion in 2022 to $22.59 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The immunosuppressants market is expected to grow from $38.35 billion in 2027 at a CAGR of 14.1%. The surge in organ transplant procedures such as kidney and liver transplants due to the rise in incidences of organ failure is the major factor driving the immunosuppressant market's growth. For instance, in June 2020, according to the United Network for Organ Sharing (UNOS), a US-based scientific and educational organization, 39,718 organ transplants were performed in the United States. Furthermore, according to the American Kidney Fund, a US-based health organization, on the national transplant waiting list in June 2022, there will be more than 106,000 people, of whom 92,000 (or 87%) are waiting for a kidney transplant in the US. The increasing number of cases of organ transplants and incidences of organ failure in patients is therefore expected to drive market growth. Stringent government regulations are expected to hamper the growth of the market. Through a stringent regulatory drug approval process, regulators such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) ensure public safety for food and drugs.For an immunosuppressant drug to be approved by the regulatory authorities, the sponsor must provide satisfactory evidence regarding the safety and efficacy of a drug in a patient with a defined clinical condition. Sponsors should submit to the Center for Drug Evaluation and Research (CDER) any information on the immunotoxicology evaluation of drugs whenever such information becomes available, for review. Many guidelines have also been adopted by the EU, including those providing general guidance, more specific guidance on quality issues, and non-clinical and clinical aspects. Therefore, the stringent regulatory and approval process for immunosuppressant drugs is projected to hamper the overall growth of the immunosuppressant market. Phenotypic personalised medicine or PPM or a hybrid of artificial intelligence and physician intervention is a new approach to overcoming the issues with immunosuppressants. For instance, tacrolimus is the most widely used immunosuppressant for patients who are undergoing organ transplantation. When the patient is in the hospital, Tacrolimus immunosuppressant levels must be checked regularly and changed frequently. A PPM approach that is based on a computational platform is used to overcome this concern. The inputs from the computational platform-based PPM approach include the past response of the patient to the dose of the drug and other drugs that are being taken, as well as current data on the liver and kidney. Using PPM, the physician can identify the optimal drug and dose combination from various possibilities. Therefore, it is believed that artificial intelligence is leading the way to not only more personalised and effective drug dosing but also enhancing physicians’ decision-making capabilities by providing clinical data rather than predicted responses. In October 2022, Amgen Inc., a US-based biopharmaceutical and biotechnology company, acquired ChemoCentryx Inc. for $3.7 billion. Through this acquisition, Amgen increases its inflammation and nephrology drug product portfolio and has three therapeutic candidates in the early stages that target chemoattractant receptors, additional inflammatory conditions, and an oral cancer checkpoint. ChemoCentryx, Inc. is a US-based biopharmaceutical company pioneering in the development and commercialization of novel drugs for cancer, autoimmune, and inflammatory illnesses. Major players in the immunosuppressant market are Astellas Pharma, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Intas Pharmaceuticals Ltd., Mylan Laboratories Inc., Pfizer, Novartis, Novartis AG, and Sanofi S.A. North America was the largest region in the immunosuppressants market in 2022. The regions covered in the global immunosuppressant market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the immunosuppressant market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The immunosuppressant market consists of sales of induction drugs, maintenance drugs, corticosteroids, and calcineurin inhibitors. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resale, either further along the supply chain or as part of other products. The global immunosuppressants market is segmented - 1) By Drug Class: Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Other Drug Classes 2) By Indication: Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The pharmaceuticals market consists of sales of pharmaceuticals and related services by entities (organizations, sole traders and partnerships) that produce pharmaceuticals used in treating diseases. Pharmaceuticals can be any type of drugs that are used for medicinal purposes, in the treatment of diseases. This industry includes establishments that produce biologics and pharmaceutical drugs. The main types of pharmaceuticals are pharmaceutical drugs and biologics. Biologics are products that are made from or contain components of living organisms. The various nature included are organic and conventional that are distributed through supermarkets/hypermarkets, convenience stores, e-commerce and others. The global pharmaceuticals market size is expected to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a compound annual growth rate (CAGR) of 9.1%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pharmaceuticals market is expected to reach $3201.02 billion in 2026 at a CAGR of 19.2%. The population profile of most countries is becoming older. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the aging population increased the patient pool of many chronic diseases such as rheumatoid arthritis, hypertension, diabetes and cancer. The increase in the patient pool drove the demand for pharmaceuticals used in the treatment of these diseases, significantly impacting market growth during this period. The biologics market growth will be hinder by severe shortage of skilled workforce for developing biologics drugs which require specialized skillsets. These skillsets are limited to some research organizations and medical equipment companies in the USA and Europe. According to a study conducted by the consulting firm Mercer, the United States will face significant healthcare worker shortages in the coming decade. The firm predicts a shortage of more than 400,000 home health aides and 29,400 nurse practitioners by 2025. This shortage will rise in competition and salaries for the limited talent pool available for biologics manufacturing, thereby limiting growth of the market during the forecast period. Pharmaceutical companies are offering drugs for customized individual treatment for various diseases. Personalized medicine, also referred to as precision medicine, aims to provide medical care according to the patient’s individual characteristics and genetic makeup. Precision therapies are increasingly being adopted as firms increasingly let go of the one-size-fits-all model for common medical conditions. Major companies such as GSK, Teva Pharmaceuticals and AstraZeneca are investing in development of personalized medicines. Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S.A, Pfizer Inc., GlaxosmithKline, F. Hoffmann-La Roche Ltd., and Merck & Co, AstraZeneca North America was the largest region in the pharmaceuticals market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceuticals market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global pharmaceuticals market is segmented - 1) By Type: Pharmaceutical Drugs, Biologics 2) By Distribution Channel: Supermarkets/Hypermarkets, Convenience Stores, E-Commerce, Others 3) By Nature: Organic, Conventional Subsegments Covered: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs, Monoclonal Antibodies (MAbs), Therapeutic Proteins, Vaccines

Hormonal contraceptive refers to a method of birth control that stops pregnancy using hormones. There are numerous types. Some can be undone, while others are irreversible. Some varieties can also aid in the prevention of STDs. The main types of products in oral contraceptive pills are injectable birth control, emergency contraceptive pills, vaginal rings, and others. Any class of synthetic steroid hormones which inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior lobe of the pituitary gland in the female body is known as oral contraceptive pills or birth control pills. The different hormones include progestin-only, and combined hormones and are used by hospitals, homecare settings, gynecologycenters, clinics, and ambulatory surgical centers. It is distributed through various channels such as drug stores, gynecology or fertility clinics, e-commerce, and others. The hormonal contraceptives market research report is one of a series of new reports from The Business Research Company that provides hormonal contraceptives market statistics, including hormonal contraceptives industry global market size, regional shares, competitors with a hormonal contraceptives market share, detailed hormonal contraceptives market segments, market trends and opportunities, and any further data you may need to thrive in the hormonal contraceptives industry. This hormonal contraceptive market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hormonal contraceptives market size will grow from $13.47 billion in 2022 to $13.78 billion in 2023 at a compound annual growth rate (CAGR) of 2.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hormonal contraceptives market size is expected to grow to $14.56 billion in 2027 at a CAGR of 1.4%. Increased awareness about the benefits and use of contraceptives is a major factor driving the hormonal contraceptives market. According to the World Health Organization (WHO), 16 million girls worldwide aged 15-19 give birth every year which accounts for approximately 11% of all births globally. To prevent these unplanned births global awareness programs such as It’s your life, it’s your future by the WHO and world contraception day was initiated. The London Summit on Family Planning urged governments, international agencies, and another private sectors to commit to improving access to voluntary family planning. This gave rise to the global partnership, Family Planning 2020 (FP2020). FP2020 has created momentum worldwide on issues such as access to contraceptives, more innovation, and greater accountability in family planning efforts. For example, India will have spent USD$3 billion by 2020 to spread awareness and improve family planning in the country. Moreover, in 2020, according to the United Nations Department of Economic and Social Affairs, about 1.1 billion women aged between 15 and 49 are considered to need family planning. The market for hormonal contraceptive drugs is restrained by the growing use of biologics in place of traditional chemical drugs. Biologics are medicines containing one or more substances derived from a biological source like micro-organisms, animal cells, or human cells. The ability to interact with specific targets puts these medicines above any other drugs, thus hampering the market of chemical-hormonal contraceptive drugs. Companies are innovating to manufacture chewable low-dose oral contraceptives that reduce side effects. The chewable contraceptive initiative was an attempt to reduce side effects while at the same time making it easier for the patients to get into a daily regimen of using this contraceptive. The pill is already being sold as an over-the-counter product. Some of the top companies that produce and sell chewable low-dose oral contraceptives, for instance, are Lupin pharmaceuticals, Walter Chilcott, and Watson pharmaceuticals. Manufacturers in the hormonal contraceptives market should abide by many strict regulations about labeling hormonal contraceptives, and are all supervised by regulatory authorities. For instance, the US FDA has drafted a new set of guidance and labeling recommendations in the hormonal contraceptives market. The main purpose of PLR is to enhance the safety and usage of the particular prescribed drug by providing healthcare providers with clear prescription information (PI). The FDA mandates all hormonal contraceptives to mention the effectiveness of the drug in preventing STDs and any other relevant information regarding the effectiveness of the drug. The FDA considers that communicating information regarding pregnancy rates to the users of these contraceptive drugs is essential for safety and effective usage. Major players in the hormonal contraceptives market are Bayer AG, Merck & Co. Inc., Pfizer, Allergan, Afaxys Inc., TevaPharma Industries Ltd., Agile Therapeutics, HLL Lifecare Limited, Lupin Pharmaceuticals Inc. and Piramal Healthcare Limited. North America was the largest region in the hormonal contraceptives market in 2022. Middle East is expected to be the fastest-growing region in the global hormonal contraceptives market during the forecast period. The regions covered in the global hormonal contraceptives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hormonal contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hormonal contraceptive market includes revenues earned by entities by blocking the release of eggs from the ovaries and thinning the lining of the uterus to prevent pregnancy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global hormonal contraceptives market is segmented - 1) By Product: Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, Other Products 2) By End Users: Hospitals, Homecare Settings, Gynaecology Centers, Clinics, Ambulatory surgical centers 3) By Hormones: Progestin-Only, Combined Hormones 4) By Distribution Channel: Drug Stores, Gynaecology/ Fertility Clinics, E-Commerce, Other Distribution Channels

Immunoglobins refer to glycoproteins, often known as antibodies, that are created by plasma cells (white blood cells). They play a crucial role in the immune response by selectively identifying and attaching to specific antigens, like viruses or bacteria, and assisting in their eradication. The main types of products in immunoglobulins are IGG, IGA, IGM, IGE, and IGD. Immunoglobulin G (IGG) is the primary stimulator of humoral immunity in extracellular fluids such as blood, lymph, and saliva. The immunoglobulins are delivered using the intravenous mode of delivery, subcutaneous mode of delivery and are used in hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency disease, myasthenia gravis, idiopathic thrombocytopenic purpura (ITP), others. The immunoglobulins market research report is one of a series of new reports from The Business Research Company that provides immunoglobulins market statistics, including immunoglobulins industry global market size, regional shares, competitors with a immunoglobulins market share, detailed immunoglobulins market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulins industry. This immunoglobulins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global immunoglobulins market size grew from $15.89 billion in 2022 to $17.16 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The immunoglobulins market size is expected to grow to $24.1 billion in 2027 at a CAGR of 8.9%. The increasing geriatric population drives the growth of the immunoglobulins market. The geriatric population is at high risk of infectious diseases and auto-immune diseases. The immunoglobulin test determines the body's ability to produce antibodies that protect it from bacteria, viruses, and allergies. According to the United Nations department of economic and social affairs (UN DESA), in 2020, the number of people aged over 65 was 727 million globally. By 2050, this figure is expected to have more than doubled, reaching over 1.5 billion people. The aging population is expected to rise from 9.3% in 2020 to 16% in 2050. Thus, the increasing geriatric population is expected to increase the demand for the immunoglobulins market during the forecast period. The launch of new offices and laboratories to boost research and development activities is shaping the immunoglobulins market. Major companies operating in the immunoglobulins sector are focused on opening new laboratories for immunoglobulins to enhance the platform technology, pipeline development, and manufacturing capabilities. For instance, in February 2021, VectorY, a fully integrated gene therapy firm, has opened offices and laboratories in the Netherlands to develop novel vectorized antibodies for muscular and neurological illnesses. In this laboratory, VectorY creates exclusive and collaborative projects based on a revolutionary AAV platform and antibody-based targeted degradation technology. The company is developing a pipeline of new vectorized antibodies to treat muscle and CNS illnesses, to enhance delivery, durability, and accessibility of specific tissues and cells, to overcome the limits of present therapies. In June 2020, CSL Behring, a US-based biopharmaceutical company acquired Vitaeris Inc., for an undisclosed amount. This acquisition accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for the treatment of chronic active antibody-mediated rejection, into CSL Behring’s portfolio. Vitaeris Inc., is a US-based clinical-stage biotechnology company. Major players in the immunoglobulins market are Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma, China Biologic Products Inc., Kedrion S.p.A., LFB group, Biotest AG, Sanquin, ADMA Biologics, Option Care Enterprises, and Shanghai Raas Blood Products Co. Ltd. North America was the largest region in the immunoglobulins market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the immunoglobulins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The immunoglobins market consists of sales of antibodies, glycoproteins, and antigens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global immunoglobulins market is segmented - 1) By Product: IGG, IGA, IGM, IGE, IGD. 2) By Mode Of Delivery: Intravenous Mode of Delivery, Subcutaneous Mode of Delivery 3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications

The immunofluorescence assay refers to equipment and consumables that operate on a technique, which allows the visualization of specific protein and antigen in infected cells based on their ability to react with specific antibodies by binding a particular antibody chemically conjugated with a fluorescent dye. It is a technique used in the laboratory to diagnose diseases of the skin, kidney, heart, cilia, and other organ systems. The main types of immunofluorescence assay include direct immunofluorescence and indirect immunofluorescence. Direct immunofluorescence refers to a laboratory technique for diagnosing skin, kidney, and other organ system diseases. Direct immunofluorescence utilizes a single antibody that is conjugated directly to fluorescence dye. The different products of immunofluorescence assay include reagents, instruments, antibodies, kits, consumables & accessories. They are used for the diagnosis of various diseases including cancer, infectious disease, autoimmune disease, and others. They are used by academic and research institutions, pharmaceutical and biotechnology companies, hospitals & diagnostic centers, and contract research organizations. The immunofluorescence assay market research report is one of a series of new reports from The Business Research Company that provides immunofluorescence assay market statistics, including immunofluorescence assay industry global market size, regional shares, competitors with an immunofluorescence assay market share, detailed immunofluorescence assay market segments, market trends and opportunities, and any further data you may need to thrive in the immunofluorescence assay industry. This immunofluorescence assay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global immunofluorescence assay market size grew from $2.92 billion in 2022 to $3.14 billion in 2023 at a compound annual growth rate (CAGR) of 7.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The immunofluorescence assay market size is expected to grow to $4.1 billion in 2027 at a CAGR of 6.9%. The increasing prevalence of chronic diseases is significantly driving the growth of the immunofluorescence assay market. The changing lifestyle, dietary habits, and improper weight management are contributing to the rapid growth in chronic conditions and a few prolonged chronic infections are leading to cancerous risk. The growing prevalence of chronic disease is expected to boost demand for immunofluorescence assays as they are widely used in diagnosis and drug development activities. For instance, according to the study published by the Centers for Disease Control and Prevention, approximately 6 in 10 adults in the USA are affected by chronic disease, and it is also accounting for $3.8 trillion in annual healthcare costs. Therefore, the increasing prevalence of chronic diseases is expected to boost demand for immunofluorescence assay during forecast period. Technological advancement is a key trend gaining popularity in the immunofluorescence assay market. The companies operating in immunofluorescence assay are focusing on developing technologically innovative products to meet specific technical demands for the diagnostic of new viruses such as COVID-19 and strengthen their market position. For instance, in March 2022, LumiraDx, a UK-based developer of point-of-care diagnostics, received emergency approval for LumiraDx SARS-CoV-2 Ag Test, a microfluidic immunofluorescence assay, designed for qualitative nucleocapsid protein antigen detection from nasal swab samples. In March 2021, Fortis Life Sciences, a US-based life sciences company, acquired Bethyl Laboratories for an undisclosed amount. Through this acquisition, Fortis will help Bethyl Laboratories to grow through its expertise in growing businesses and the strong product line difference. Bethyl Laboratories is a US-based premium antibody company. Major players in the immunofluorescence assay market are Thermo Fisher Scientific, Inc., Abcam plc, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Werfen Company, Merck KGaA, Agilent Technologies, Becton Dickinson and Company, Maxvision Biosciences Inc., Zyagen, J. Mitra & Co. Pvt. Ltd., AESKU GROUP GmbH, Vector Laboratories, Inc., EpiGentek Group, and Elabscience, Inc. North America was the largest region in the immunofluorescence assay market in 2022, and it is also expected to be the fastest-growing region in the forecast period. The regions covered in the immunofluorescence assay market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the immunofluorescence assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The immunofluorescence assay market consists of sales of indirect IF complement-fixation (IF-CF), and double IF. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global immunofluorescence assay market is segmented - 1) By Type: Direct Immunofluorescence, Indirect Immunofluorescence 2) By Product: Reagents, Instruments, Antibodies, Kits, Consumables and Accessories 3) By Disease: Cancer, Infectious Disease, Cardiovascular Diseases, Autoimmune Diseases, Other Diseases 4) By End User: Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Hospitals & Diagnostic Centers

Cellular immunotherapy refers to a sort of immunotherapy in which a patient receives T cells, an immune cell, to aid the body in fighting diseases like cancer. It is a cutting-edge kind of treatment that uses the body's immune system to combat cancer. The main therapies of cellular immunotherapy are tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy that involves extracting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro, and then infusing them back into patients to treat them. The various primary indications include b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, and others, and are used for the treatment of prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumours, lung cancer, and others. The cellular immunotherapy market research report is one of a series of new reports from The Business Research Company that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cellular immunotherapy market grew from $4.3 billion in 2022 to $5.03 billion in 2023 at a compound annual growth rate (CAGR) of 17.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cellular immunotherapy market is expected to grow from $8.59 billion in 2027 at a CAGR of 14.3%. Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period. Companies are focusing on developing new cellular immunotherapies for treating different diseases. For instance, in June 2022, according to a report published by the Cancer Research Institute, a US-based nonprofit organization devoted solely to developing immunotherapy for the prevention, treatment, and eventual eradication of all cancers, in the worldwide immuno-oncology pipeline as of April 2022, there were 2,756 active cell therapy drugs, up 36% from the landscape analysis of 2021 that revealed 2,031 such agents but also a slight slowdown from the 43% growth in the previous year. The rapid growth in the development of cellular immunotherapy in clinical and preclinical stages in 2020 as compared to that in 2019 is projected to expand the landscape of cellular immunotherapy. Subsequently, generating higher revenues for the cellular immunotherapy market. The high cost of cellular immunotherapies is anticipated to hinder cellular immunotherapy’s market growth. CAR-T therapy is a type of cellular immunotherapy and only two have been approved in the USA. The price of Yescarta and Kymriah is more than $350,000 per treatment in the USA, which is highly unaffordable for a majority of the patients, especially with low income. The high cost of cellular immunotherapies discourages patients to opt for this drug, thereby, impacting the demand and the market negatively. Companies in the cellular immunotherapy market are focusing on developing off-the-shelf allogeneic therapies for new and improved cancer treatment. Off-the-shelf allogeneic therapies are produced from the cells of donors instead of the patient's cells, as in the case of autologous therapy. Their non-customized nature provides advantages such as cost-effectiveness, large scale, fast production, and quality control. For instance, in May 2022, Novartis AG, a Switzerland-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of drugs, announced that after two or more lines of systemic therapy, the US Food and Drug Administration (FDA) has given expedited approval for Kymriah® (tisagenlecleucel) to treat adult patients with relapsed or refractory (r/r) follicular lymphoma (FL). In addition, Acepodia, a US-based next-generation cell immuno-technology company, will begin a phase 1 clinical trial in August 2020 to evaluate ACE1702, an allogeneic, off-the-shelf NK cell therapy, for the treatment of solid tumors. In April 2020, resTORbio, Inc., a US-based biopharmaceutical company specialising in the development and commercialization of drugs used for the treatment of aging-related diseases, merged with Adicet Bio, Inc., a biopharmaceutical company, for an undisclosed amount. Both the companies continue their operations as ‘Adicet Bio’. This merger is expected to help the companies advance allogeneic gamma-delta CAR-T cell therapy technology. Adicet Bio, Inc. is a US-based company specialising in the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications. Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC., JW CreaGene Co. Ltd., Green Cross Corp. (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., and Roche. The regions covered in the global cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cellular immunotherapy market includes revenues earned by entities by inventing, developing, administering, and understanding engineered immune effector cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply c either further along the supply chain or as part of other products. The global cellular immunotherapy market is segmented - 1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, and Natural Killer (NK) Cell Therapy 2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin Lymphoma, Other Primary Indications 3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumour, Lung Cancer, Other Applications